CBIO - Catalyst Biosciences, Inc.

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Show:
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2022
31/12/2021
31/12/2020
31/12/2019
Total revenue
3,234
794
7,338
20,948
0
Cost of revenue
3,252
798
7,380
9,163
-
Gross profit
-18
-4
-42
11,785
-
Operating expenses
Research development
28,512
13,037
68,889
52,975
43,859
Selling general and administrative
17,365
17,366
18,963
16,180
13,418
Total operating expenses
45,877
30,403
87,852
69,155
57,277
Operating income or loss
-45,895
-30,407
-87,894
-57,370
-57,277
Total other income/expenses net
21,976
21,976
-78
568
-46
Income before tax
11,883
-7,894
-87,933
-56,241
-55,178
Income tax expense
348
348
-
-
-
Income from continuing operations
11,883
-8,242
-87,933
-56,241
-55,178
Net income
11,883
-8,242
-87,933
-56,241
-55,178
Net income available to common shareholders
11,883
-8,242
-87,933
-56,241
-55,178
Basic EPS
-
-0.26
-2.87
-2.93
-4.60
Diluted EPS
-
-0.26
-2.87
-2.93
-4.60
Basic average shares
-
31,546
30,641
19,179
12,004
Diluted average shares
-
31,546
30,641
19,179
12,004
EBITDA
-
-30,177
-87,604
-57,370
-57,277